Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings
1 Gynecology Department, San Raffaele Hospital, Milan, Italy
2 Radiotherapy Department, San Raffaele Hospital, Milan, Italy
3 Gynecology Department Ospedali Riuniti, Bergamo, Italy
4 CNR IBSM, University of Milano-Bicocca, Nuclear Medicine Department, San Raffaele Hospital, Milan, Italy
BMC Cancer 2006, 6:198 doi:10.1186/1471-2407-6-198Published: 25 July 2006
There is still much debate about the best adjuvant therapy after surgery for endometrial cancer (EC) and there are no current guidelines. Radiotherapy (RT) alone does not seem to improve overall survival. We investigated whether concomitant Paclitaxel (P) and RT gave better clinical results.
Twenty-three patients with high-risk EC (stage IIB, IIIA, IIIC or IC G3 without lymphadenectomy or with aneuploid tumor) underwent primary surgery and were then referred for adjuvant therapy. P was given at a dose of 60 mg/m2 once weekly for five weeks during RT, which consisted of a total radiation dose of 50.4 Gy. Three further weekly cycles of P at a dose of 80 mg/m2 were given at the end of RT. Overall survival and disease-free survival were calculated from the time of surgery. Patterns of failure were recorded by the sites of failure.
A total of 157 cycles of P were administered both during radiotherapy and consolidation chemotherapy.
Relapses occurred in five patients (21.7%). Median time to recurrence was 18.6 months (range 3–28). Survival rate for all the patients was 78.2%. Overall survival for the patients who completed chemo-radiation was of 81%. In this group median time to recurrence was 19.2 months (range 3–28). All recurrences were outside the radiation field. Mortality rate was 14.2%.
This small series demonstrates pelvic radiotherapy in combination with weakly P followed by three consolidation chemotherapy cycles as an effective combined approach in high risk endometrial carcinoma patients.